Mycobacterium bovis bacillus Calmette-GuéRin-induced macrophage cytotoxicity against bladder cancer cells

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Luo, Yi ^a   Knudson, Matthew J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL KILLING; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TH1 CELL; TH2 CELL; TRANSITIONAL CELL CARCINOMA; ANIMAL; BLADDER TUMOR; CARCINOMA; CATTLE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; PATHOLOGY; TH1 TH2 BALANCE;

ANIMALS; BCG VACCINE; CARCINOMA; CATTLE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGES; MYCOBACTERIUM BOVIS; TH1-TH2 BALANCE; URINARY BLADDER NEOPLASMS;

EID: 77957876452     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/357591     Document Type: Review

References (74)

1. Morales A., Eidinger D., Bruce A. W., Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors Journal of Urology 1976 116 2 180 183
2. Alexandroff A. B., Jackson A. M., O'Donnell M. A., James K., BCG immunotherapy of bladder cancer: 20 years on Lancet 1999 353 9165 1689 1694
3. Patard J. J., Saint F., Velotti F., Abbou C. C., Chopin D. K., Immune response following intravesical bacillus Calmette-Guerin instillations in superficial madder cancer: a review Urological Research 1998 26 3 155 159
4. Ratliff T. L., Ritchey J. K., Yuan J. J. J., Andriole G. L., Catalona W. J., T-cell subsets required for intravesical BCG immunotherapy for bladder cancer Journal of Urology 1993 150 3 1018 1023
5. Wang R., Rogers A. M., Ratliff T. L., Russell J. H., CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors Journal of Immunology 1996 157 7 2961 2968
6. Brandau S., Riemensberger J., Jacobsen M., Kemp D., Zhao W., Zhao X., Jocham D., Ratliff T. L., Bhle A., NK cells are essential for effective BCG immunotherapy International Journal of Cancer 2001 92 5 697 702
7. Liu W., O'Donnell M. A., Chen X., Han R., Luo Y., Recombinant bacillus Calmette-Gurin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro Cancer Immunology, Immunotherapy 2009 58 10 1647 1655
8. Wang M.-H., Flad H.-D., Bhle A., Chen Y.-Q., Ulmer A. J., Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines Immunology Letters 1991 27 3 191 198
9. Shemtov M. M., Cheng D. L.-W., Kong L., Shu W.-P., Sassaroli M., Droller M. J., Liu B. C.-S., LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy Journal of Urology 1995 154 1 269 274
10. Thanhuser A., Bhle A., Flad H.-D., Ernst M., Mattern T., Ulmer A. J., Induction of bacillus-Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro Cancer Immunology Immunotherapy 1993 37 2 105 111
11. Brandau S., Suttmann H., Riemensberger J., Seitzer U., Arnold J., Durek C., Jocham D., Flad H.-D., Bhle A., Perforin-mediated lysis of tumor cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated killer cells Clinical Cancer Research 2000 6 9 3729 3738
12. Bhle A., Thanhuser A., Ulmer A. J., Ernst M., Flad H.-D., Jocham D., Dissecting the immunobiological effects of Bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon Journal of Urology 1993 150 6 1932 1937
13. Kawashima T., Norose Y., Watanabe Y., Enomoto Y., Narazaki H., Watari E., Tanaka S., Takahashi H., Yano I., Brenner M. B., Sugita M., Cutting edge: major CD8 T cell response to live bacillus Calmette-Gurin is mediated by CD1 molecules Journal of Immunology 2003 170 11 5345 5348
14. Wang M.-H., Chen Y.-Q., Gercken J., Ernst M., Bhle A., Flad H.-D., Ulmer A. J., Specific activation of human peripheral blood / + T lymphocytes by sonicated antigens of Mycobacterium tuberculosis: role in vitro in killing human bladder carcinoma cell lines Scandinavian Journal of Immunology 1993 38 3 239 246
15. Higuchi T., Shimizu M., Owaki A., Takahashi M., Shinya E., Nishimura T., Takahashi H., A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth Cancer Immunology, Immunotherapy 2009 58 8 1245 1255
16. Naoe M., Ogawa Y., Takeshita K., Morita J., Iwamoto S., Miyazaki A., Yoshida H., Bacillus Calmette-Gurin-pulsed dendritic cells stimulate natural killer T cells and T cells International Journal of Urology 2007 14 6 532 538
17. Emoto M., Emoto Y., Buchwalow I. B., Kaufmann S. H. E., Induction of IFN- -producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guerin European Journal of Immunology 1999 29 2 650 659
18. Suttmann H., Riemensberger J., Bentien G., Schmaltz D., Stckle M., Jocham D., Bhle A., Brandau S., Neutrophil granulocytes are required for effective Bacillus Calmette-Gurin immunotherapy of bladder cancer and orchestrate local immune responses Cancer Research 2006 66 16 8250 8257
19. Rosevear H. M., Lightfoot A. J., O'Donnell M. A., Griffith T. S., The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Gurin (BCG) immunotherapy for urothelial carcinoma of the bladder Cancer Metastasis Reviews 2009 28 3-4 345 353
20. Klostergaard J., Stoltje P. A., Kull F. C. Jr., Tumoricidal effector mechanisms of murine BCG-activated macrophages: role of TNF in conjugation-dependent and conjugation-independent pathways Journal of Leukocyte Biology 1990 48 3 220 228
21. Klostergaard J., Leroux M. E., Hung M.-C., Cellular models of macrophage tumoricidal effector mechanisms in vitro. Characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro Journal of Immunology 1991 147 8 2802 2808
22. Schwamberger G., Flesch I., Ferber E., Tumoricidal effector molecules of murine macrophages Pathobiology 1991 59 4 248 253
23. Bhle A., Gerdes J., Ulmer A. J., Hofstetter A. G., Flad H.-D., Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall Journal of Urology 1990 144 1 53 58
24. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F., Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall Journal of Urology 1992 147 6 1636 1642
25. Peuchmaur M., Benoit G., Vieillefond A., Chevalier A., Lemaigre G., Martin E. D., Jardin A., Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus calmette-guerin Urological Research 1989 17 5 299 303
26. Saint F., Patard J. J., Groux Muscatelli B., Lefrere Belda M. A., Gil Diez De Medina S., Abbou C. C., Chopin D. K., Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Gurin treatment British Journal of Urology International 2001 88 6 602 610
27. De Boer E. C., De Jong W. H., Van der Meijden A. P. M., Steerenberg P. A., Witjes F., Vegt P. D. J., Debruyne F. M. J., Ruitenberg E. J., Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis Urological Research 1991 19 1 45 50
28. De Boer E. C., De Jong W. H., Van der Meijden A. P. M., Steerenberg P. A., Witjes J. A., Vegt P. D. J., Debruyne F. M. J., Ruitenberg E. J., Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin Cancer Immunology Immunotherapy 1991 33 6 411 416
29. De Boer E. C., De Jong W. H., Steerenberg P. A., Van Der Meijden A. P. M., Aarden L. A., Debruyne F. M. J., Ruitenberg E. J., Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with Bacillus Calmette-Guerine In Vivo 1991 5 6 671 678
30. Bhle A., Nowc N. CH., Ulmer A. J., Musehold J., Gerdes J., Hofstetter A. G., Flad H.-D., Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy Journal of Urology 1990 144 1 59 64
31. Thalmann G. N., Sermier A., Rentsch C., Mhrle K., Cecchini M. G., Studer U. E., Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin Journal of Urology 2000 164 6 2129 2133
32. De Reijke T. M., De Boer E. C., Kurth K. H., Schamhart D. H. J., Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value Journal of Urology 1996 155 2 477 482
33. Saint F., Patard J. J., Maille P., Soyeux P., Hoznek A., Salomon L., Abbou C. C., Chopin D. K., Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer Journal of Urology 2002 167 1 364 367
34. Nadler R., Luo Y., Zhao W., Ritchey J. K., Austin J. C., Cohen M. B., O'Donnell M. A., Ratliff T. L., Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Gurin (BCG) mediated antitumour activity Clinical and Experimental Immunology 2003 131 2 206 216
35. Luo Y., Chen X., O'Donnell M. A., Mycobacterium bovis bacillus Calmette-Gurin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo Clinical and Experimental Immunology 2007 147 2 370 378
36. Wang J., Wakeham J., Harkness R., Xing Z., Macrophages are a significant source of type 1 cytokines during mycobacterial infection Journal of Clinical Investigation 1999 103 7 1023 1029
37. Atkinson S., Valadas E., Smith S. M., Lukey P. T., Dockrell H. M., Monocyte-derived macrophage cytokine responses induced by M. bovis BCG Tubercle and Lung Disease 2000 80 4-5 197 207
38. Calorini L., Bianchini F., Mannini A., Mugnai G., Balzi M., Becciolini A., Ruggieri S., IFN and TNF account for a pro-clonogenic activity secreted by activated murine peritoneal macrophages Clinical and Experimental Metastasis 2002 19 3 259 264
39. Baran J., Baj-Krzyworzeka M., Weglarczyk K., Ruggiero I., Zembala M., Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae Cancer Immunology, Immunotherapy 2004 53 12 1127 1134
40. Pryor K., Goddard J., Goldstein D., Stricker P., Russell P., Golovsky D., Penny R., Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing British Journal of Cancer 1995 71 4 801 807
41. Yamada H., Matsumoto S., Matsumoto T., Yamada T., Yamashita U., Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2 Journal of Urology 2000 164 2 526 531
42. Yamada H., Matsumoto S., Matsumoto T., Yamada T., Yamashita U., Enhancing effect of an inhibitor of nitric oxide synthesis on Bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro Japanese Journal of Cancer Research 2000 91 5 534 542
43. Yamada H., Kuroda E., Matsumoto S., Matsumoto T., Yamada T., Yamashita U., Prostaglandin E2 down-regulates viable Bacille Calmette-Gurin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro Clinical and Experimental Immunology 2002 128 1 52 58
44. Luo Y., Yamada H., Chen X., Ryan A. A., Evanoff D. P., Triccas J. A., O'Donnell M. A., Recombinant Mycobacterium bovis bacillus Calmette-Gurin (BCG) expressing mouse IL-18 augmente Th1 immunity and macrophage cytotoxicity Clinical and Experimental Immunology 2004 137 1 24 34
45. Luo Y., Yamada H., Evanoff D. P., Chen X., Role of Th1-stimulating cytokines in bacillus Calmette-Gurin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells Clinical and Experimental Immunology 2006 146 1 181 188
46. Luo Y., Han R., Evanoff D. P., Chen X., Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Gurin (BCG)-induced macrophage cytotoxicity against bladder cancer cells Clinical and Experimental Immunology 2010 160 3 359 368
47. Ratliff T. L., Bacillus Calmette-Guerin (BCG): mechanism of action in superficial bladder cancer Urology 1991 37 5, supplement 8 11
48. Bevers R. F. M., Kurth K.-H., Schamhart D. H. J., Role of urothelial cells in BCG immunotherapy for superficial bladder cancer British Journal of Cancer 2004 91 4 607 612
49. Smith W. L., Garavito R. M., DeWitt D. L., Prostaglandin endoperoxide H syntheses (cyclooxygenases)-1 and -2 Journal of Biological Chemistry 1996 271 52 33157 33160
50. Arnold J., De Boer E. C., O'Donnell M. A., Bhle A., Brandau S., Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon- Journal of Immunotherapy 2004 27 2 116 123
51. Horinaga M., Harsch K. M., Fukuyama R., Heston W., Larchian W., Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model Urology 2005 66 2 461 466
52. DesJardin L. E., Kaufman T. M., Potts B., Kutzbach B., Yi H., Schlesinger L. S., Mycobacterium tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, Fc RII and the mannose receptor Microbiology 2002 148 10 3161 3171
53. Mustafa T., Phyu S., Nilsen R., Bjune G., Jonsson R., Increased expression of Fas ligand on Mycobacterium tuberculosis infected macrophages: a potential novel mechanism of immune evasion by Mycobacterium tuberculosis? Inflammation 1999 23 6 507 521
54. Diehl G. E., Yue H. H., Hsieh K., Kuang A. A., Ho M., Morici L. A., Lenz L. L., Cado D., Riley L. W., Winoto A., TRAIL-R as a negative regulator of innate immune cell responses Immunity 2004 21 6 877 889
55. Saito S., Nakano M., Nitric oxide production by peritoneal macrophages of Mycobacterium bovis BCG-infected or non-infected mice: regulatory roles of T lymphocytes and cytokines Journal of Leukocyte Biology 1996 59 6 908 915
56. Petricevich V. L., Alves R. C. B., Role of cytokines and nitric oxide in the induction of tuberculostatic macrophage functions Mediators of Inflammation 2000 9 6 261 269
57. Hawkyard S. J., Jackson A. M., Prescott S., James K., Chisholm G. D., The effect of recombinant cytokines on bladder cancer cells in vitro Journal of Urology 1993 150 2 514 518
58. Choi S.-C., Oh H.-M., Park J.-S., Han W.-C., Yoon K.-H., Kim T.-H., Yun K.-J., Kim E.-C., Nah Y.-H., Cha Y.-N., Chung H.-T., Jun C.-D., Soluble factor from murine bladder tumor-2 cell elevates nitric oxide production in macrophages and enhances the taxol-mediated macrophage cytotoxicity on tumor cells Cancer Investigation 2003 21 5 708 719
59. O'Donnell M. A., Luo Y., Hunter S. E., Chen X., Hayes L. L., Clinton S. K., The essential role of interferon- during interleukin-12 therapy for murine transitional cell carcinoma of the bladder Journal of Urology 2004 171 3 1336 1342
60. Ware C. F., VanArsdale S., VanArsdale T. L., Apoptosis mediated by the TNF-related cytokine and receptor families Journal of Cellular Biochemistry 1996 60 1 47 55
61. Laster S. M., Wood J. G., Gooding L. R., Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis Journal of Immunology 1988 141 8 2629 2634
62. Umansky V., Schirrmacher V., Nitric oxide-induced apoptosis in tumor cells Advances in Cancer Research 2001 82 107 131
63. Greent S. J., Scheller L. F., Marletta M. A., Seguin M. C., Klotz F. W., Slayter M., Nelson B. J., Nacy C. A., Nitric Oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens Immunology Letters 1994 43 1-2 87 94
64. Kindler V., Sappino A.-P., Grau G. E., Piguet P.-F., Vassalli P., The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection Cell 1989 56 5 731 740
65. Zhou A., Chen Z., Rummage J. A., Jiang H., Kolosov M., Kolosova I., Stewart C. A., Leu R. W., Exogenous interferon- induces endogenous synthesis of interferon- and- by murine macrophages for induction of nitric oxide synthase Journal of Interferon and Cytokine Research 1995 15 10 897 904
66. Huguenin S., Vacherot F., Fleury-Feith J., Riffaud J.-P., Chopin D. K., Bolla M., Jaurand M.-C., Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines Cancer Letters 2005 218 2 163 170
67. Morcos E., Jansson O. T., Adolfsson J., Kratz G., Peter Wiklund N., Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines Urology 1999 53 6 1252 1257
68. Jansson O. T., Morcos E., Brundin L., Lundberg J. O. N., Adolfsson J., Sderhll M., Wiklund N. P., The role of nitric oxide in bacillus Calmette-Gurin mediated anti-tumour effects in human bladder cancer British Journal of Cancer 1998 78 5 588 592
69. Riemensberger J., Bhle A., Brandau S., IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer Clinical and Experimental Immunology 2002 127 1 20 26
70. De Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., De Vries J. E., Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes Journal of Experimental Medicine 1991 174 5 1209 1220
71. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A., IL-10 inhibits cytokine production by activated macrophages Journal of Immunology 1991 147 11 3815 3822
72. Cenci E., Romani L., Mencacci A., Spaccapelo R., Schiaffella E., Puccetti P., Bistoni F., Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans European Journal of Immunology 1993 23 5 1034 1038
73. Bogdan C., Vodovotz Y., Nathan C., Macrophage deactivation by interleukin 10 Journal of Experimental Medicine 1991 174 6 1549 1555
74. Chomarat P., Banchereau J., Davoust J., Palucka A. K., IL-6 switches the differentiation of monocytes from dendritic cells to macrophages Nature Immunology 2000 1 6 510 514